Life after surgery for neuroendocrine tumors
Part of Cancer clinical trials.
This study follows people after surgery to remove neuroendocrine tumors (NETs) from the stomach, intestines, or pancreas. It aims to understand long-term outcomes and quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a well-differentiated neuroendocrine tumor (grade 1, 2, or 3) confirmed by biopsy or imaging tests like CT, MRI, or a special PET scan (SSTR-PET).
- The tumor is located in the stomach, intestines (midgut), or pancreas and is either localized, loco-regional, or has spread (metastatic) but can be removed with surgery.
- You agree to have surgery to remove the tumor.
- You must be able to answer study questionnaires in the local language.
- You do not have a more aggressive type called neuroendocrine carcinoma.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with advanced neuroendocrine tumors (NETs) that cannot be removed by surgery or have spread. Its goal is to see how long patients can live without having serious side effects from treatment, so doctors can better understand which treatments are worth the risks.
This study looks at whether removing the main tumor in the small intestine (along with standard treatment) helps people with small intestinal neuroendocrine tumors that have spread and cannot be cured. It compares this approach to treatment without surgery.
This trial tests whether adding chemotherapy to a standard treatment (PRRT) works better than PRRT alone for people with certain types of digestive tract or pancreatic neuroendocrine tumors. It is for those whose tumors have higher activity on scans or are growing.
This study examines how doctors treat gastroenteropancreatic neuroendocrine tumors (rare slow-growing cancers of the stomach, pancreas, or intestines) and how patients respond. Researchers will review medical records from 2018–2025 to understand which treatments work best and help improve care for future patients.
This study looks at how tumor and patient factors affect treatment response in well-differentiated GEP-NENs (neuroendocrine tumors of the digestive system). It may help doctors understand which treatments work best for people like you.
This trial tests if removing as much tumor as possible through surgery before a targeted radiation therapy (PRRT) can help people with well-differentiated neuroendocrine tumors that have spread to the liver. The goal is to see if this approach works better than radiation therapy alone.
Hear when a new Neuroendocrine (NE) Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.